MARCO

United Aqua Group Members Now Have Access to Aiper Cordless Robotic Pool Cleaners Through a New Partnership

Retrieved on: 
Thursday, February 29, 2024
Circuit party, System, UAG, Life, Conference, MARCO, Circuit, Partnership

MARCO ISLAND, Fla., Feb. 29, 2024 /PRNewswire/ -- Aiper, the global creator of innovative cordless robotic pool cleaners, and United Aqua Group (UAG), one of the nation's largest professional pool construction, retail, and service industry organizations, together announce a new strategic partnership. Announced during the United Aqua Group Annual Conference in Marco Island, Florida (February 25-29), where Aiper was the official sponsor, the new collaboration will give UAG members across America access to advanced technologies designed to achieve a more efficient way of tackling pool maintenance through smarter product solutions, specifically the Aiper line of cordless robotic pool cleaners. Starting today, members can shop for Aiper products on the UAG website at an affordable price point.

Key Points: 
  • MARCO ISLAND, Fla., Feb. 29, 2024 /PRNewswire/ -- Aiper , the global creator of innovative cordless robotic pool cleaners, and United Aqua Group (UAG), one of the nation's largest professional pool construction, retail, and service industry organizations, together announce a new strategic partnership.
  • Announced during the United Aqua Group Annual Conference in Marco Island, Florida (February 25-29), where Aiper was the official sponsor, the new collaboration will give UAG members across America access to advanced technologies designed to achieve a more efficient way of tackling pool maintenance through smarter product solutions, specifically the Aiper line of cordless robotic pool cleaners.
  • Starting today, members can shop for Aiper products on the UAG website at an affordable price point.
  • "UAG is proud to partner with Aiper, a distinguished trailblazer in technology and innovation," says Craig Goodson, President of the United Aqua Group.

Rare Double Front Penthouse at The Prince Enters Market for $7.8 Million

Retrieved on: 
Monday, December 18, 2023
MARCO, Heart, Paint, Hotel

MARCO ISLAND, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- An incredible double-front penthouse on Marco Island’s Residents Beach is entering the market for $7,800,000. Located at 176 S Collier Boulevard PH-A, the residence was designed for coastal luxury and is offered turnkey. Originally crafted for the developer of The Prince, this iconic beachfront address is marketed exclusively by Jim and Nikki Prange of Premier Sotheby’s International Realty’s Marco Island office. The listing details may be viewed here.

Key Points: 
  • MARCO ISLAND, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- An incredible double-front penthouse on Marco Island’s Residents Beach is entering the market for $7,800,000.
  • Located at 176 S Collier Boulevard PH-A, the residence was designed for coastal luxury and is offered turnkey.
  • Originally crafted for the developer of The Prince, this iconic beachfront address is marketed exclusively by Jim and Nikki Prange of Premier Sotheby’s International Realty’s Marco Island office.
  • Additionally, The Prince offers a community pool, fitness center with sauna, tennis/pickleball, guest suites, covered parking and more.

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

Retrieved on: 
Monday, May 22, 2023
GDF11, Mouse, Endothelial dysfunction, Heart failure, TGF, Heart, PAH, Serum, ATS, Matrix metalloproteinase inhibitor, Cardiac fibrosis, SMAD, Pharmacokinetics, Woman, IL-6, Research, Part, Inflammation, Biomarker, American Thoracic Society, SMAD2, Administration, TAC, MARCO, Asilomar International Conference on Climate Intervention Technologies, Patient, Vascular remodelling in the embryo, Orthostatic hypertension, Therapy, Hypoxia, Conference, Endothelium, Safety, KROS, Pharmaceutical industry, Medical device, Extractive metallurgy, Vaccine, Trapping, Fibrosis

“We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.

Key Points: 
  • “We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.
  • The preclinical presentations demonstrate observed ligand selectivity of KER-012 and changes in inflammation and fibrosis in models of PAH and cardiovascular diseases.
  • Keros reported preliminary topline data from the Part 1 single ascending dose portion of the trial in May 2022, and additional preliminary clinical data from the Part 2 multiple ascending dose portion of the trial in September 2022.
  • HPAECs and HPASMCs were treated with activin A, GDF11, or bone morphogenetic protein 9 (“BMP9”) in the presence of KER-012.

Landmark HR: Transforming HR Management Through Customized, Cost-Effective Solutions

Retrieved on: 
Monday, April 10, 2023
ISLAND, Growth, MARCO, Acquisition, Landmark, Face, Business travel, Management

MARCO ISLAND, Fla., April 10, 2023 /PRNewswire-PRWeb/ -- Landmark HR, a strategic HR management partner committed to providing personalized and cost-effective HR solutions, is excited to announce it has officially launched. Landmark HR empowers businesses of all sizes by removing the administrative burden of HR, allowing them to redirect their resources toward growth and continued success.

Key Points: 
  • Landmark HR, a nationwide and strategic HR management partner committed to providing personalized and cost-effective HR solutions, is excited to announce it has officially launched.
  • Landmark HR empowers businesses of all sizes by removing the administrative burden of HR, allowing them to redirect their resources toward growth and continued success.
  • MARCO ISLAND, Fla., April 10, 2023 /PRNewswire-PRWeb/ -- Landmark HR, a strategic HR management partner committed to providing personalized and cost-effective HR solutions, is excited to announce it has officially launched.
  • As a trusted advisor and partner, Landmark HR offers a comprehensive suite of services, including talent acquisition, employee training and development, performance management, and HR compliance.

Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement

Retrieved on: 
Thursday, March 23, 2023
Oncology, Health, Other Science, General Health, Clinical Trials, Research, Science, Immunotherapy, Myelocyte, Gilead Sciences, Therapy, Gilead, MARCO, TREM2, Pembrolizumab, Tumor microenvironment, TREM1, Safety, Pharmaceutical industry, Pionýr, IND

Pionyr Immunotherapeutics, Inc ., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s anti-tumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, today announced that Pionyr and Gilead Sciences, Inc. (Nasdaq: GILD) have mutually agreed to change their 2020 exclusive option agreements.

Key Points: 
  • Pionyr Immunotherapeutics, Inc ., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s anti-tumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, today announced that Pionyr and Gilead Sciences, Inc. (Nasdaq: GILD) have mutually agreed to change their 2020 exclusive option agreements.
  • Gilead has waived its exclusive option to acquire Pionyr and certain other rights under the 2020 agreements.
  • In 2020, Gilead paid $275 million for its equity stake in Pionyr and agreed to fund Pionyr’s clinical and research activities in exchange for an exclusive option to acquire Pionyr for a pre-set price and contingent payments.
  • As part of this agreement, Gilead waives its exclusive option to acquire Pionyr.

InterPro Solutions Wins IMC Solution Awards for EZMaxPlanner and EZMaxVendor at IMC 2022

Retrieved on: 
Wednesday, December 7, 2022
Conference, Electricity, MARCO, ISLAND, Enterprise asset management, Work, InterPro, Job, EAM, Maintenance, IMC, Organization, Asset management, Mobile enterprise asset management, IBM, Interest, Risk management

MARCO ISLAND, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- From IMC 2022, InterPro Solutions, which offers the first and only suite of mobile solutions designed exclusively for IBM Maximo®, announced today that it has won two Solution Awards at the 2022 International Maintenance Conference (IMC 2022). Its unique mobile application for managing service vendors, EZMaxVendor, won the Work Execution Management category, and its mobile solution for Maximo scheduling and planning, EZMaxPlanner, won the Asset Management category.

Key Points: 
  • InterPro Solutions is lauded for their innovative mobile solutions for managing field service vendors and Maximo scheduling & planning.
  • MARCO ISLAND, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- From IMC 2022, InterPro Solutions , which offers the first and only suite of mobile solutions designed exclusively for IBM Maximo®, announced today that it has won two Solution Awards at the 2022 International Maintenance Conference ( IMC 2022 ).
  • Its unique mobile application for managing service vendors, EZMaxVendor, won the Work Execution Management category, and its mobile solution for Maximo scheduling and planning, EZMaxPlanner, won the Asset Management category.
  • EZMaxVendor, InterPro’s application for managing field service vendors, was initially released in February 2021.

Pionyr Immunotherapeutics’ MARCO-targeting Antibody Program, PY265, for Treatment of Solid Tumors Featured at SITC 2022

Retrieved on: 
Monday, November 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Immunosuppression, Cytokine, Research, New Enterprise Associates, Therapy, Tumor microenvironment, Growth, Transcription activator-like effector nuclease, Cancer, MARCO, Sofinnova, Mouse, Neoplasm, TME, Poster, Chemokine, Phosphorylation, Immunotherapy, Tams, Myelocyte, Gilead, TREM2, ADCC, TREM1, Gilead Sciences, CPI, MDSC, Society, SITC, Society for Immunotherapy of Cancer, Program, Tumor-associated macrophage, Pharmaceutical industry, Vaccine, Pionýr

By reprogramming myeloid cells, PY265 remodels the TME to unleash anti-tumor immunity and converts CPI-resistant tumors into treatment-responsive tumors.

Key Points: 
  • By reprogramming myeloid cells, PY265 remodels the TME to unleash anti-tumor immunity and converts CPI-resistant tumors into treatment-responsive tumors.
  • The poster will be available on the Pionyr company website after the completion of the SITC poster session.
  • Pionyr has developed a therapeutic platform called Myeloid TuningTM, a process that rebalances the tumor microenvironment (TME) to promote anti-tumor immunity.
  • Pionyr is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics after checkpoint inhibitors.

Pionyr Immunotherapeutics to Present on Myeloid Tuning Platform and TREM1 Targeting Antibody Program at the Tumor Myeloid-Directed Therapies Summit

Retrieved on: 
Thursday, June 16, 2022
Oncology, Health, Biometrics, General Health, Research, Science, Pharmaceutical, Sofinnova, Myelocyte, Therapy, Tumor-associated macrophage, Chief medical informatics officer, Tumor microenvironment, Immunosuppression, Immunotherapy, Cancer, ADCC, TME, Gilead, Metastasis, TREM1, New Enterprise Associates, Gilead Sciences, MARCO, TAM, TREM2, Pionýr, Tams, Vaccine, Pharmaceutical industry, Neoplasm

The presentation titled, Reprogramming TREM1+ Myeloid Cells to Overcome Immunotherapy Resistance in Solid Tumors, takes place at the 2nd Tumor Myeloid Directed Therapies Summit on June 16, 2022.

Key Points: 
  • The presentation titled, Reprogramming TREM1+ Myeloid Cells to Overcome Immunotherapy Resistance in Solid Tumors, takes place at the 2nd Tumor Myeloid Directed Therapies Summit on June 16, 2022.
  • PY159 is a humanized monoclonal antibody that specifically binds triggering receptor expressed on myeloid cells 1 (TREM1).
  • Pionyr has developed a therapeutic platform called Myeloid Tuning, a process that rebalances the tumor microenvironment (TME) to promote anti-tumor immunity.
  • Pionyr is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics after checkpoint inhibitors.

Dan Skelly Joins Platinum Real Estate In Florida

Retrieved on: 
Wednesday, April 6, 2022
ISLAND, Adult, Life, Skelly, MARCO, Time, Real estate

MARCO ISLAND, Fla., April 5, 2022 /PRNewswire/ -- Dan Skelly joins Platinum Real Estate in Marco Island, Florida. Dan Skelly, the current broker/owner at Orson Hill Realty in Colorado, is very excited to get back to the beach for part of the year. Dan lived in Florida for the majority of his adult life and loves everything about the sunshine state. He especially loves the real estate market. After 10 years as a broker in Colorado Dan wanted to branch out to the fast-paced Florida real estate market. Dan will be working from the Platinum Real Estate office in Marco Island but will work with buyers, sellers, and investors all over Southwest Florida and Colorado.

Key Points: 
  • Dan Skelly, broker/owner of Orson Hill Realty in Colorado, has just joined forces with Platinum Real Estate in Marco Island, FL.
  • MARCO ISLAND, Fla., April 5, 2022 /PRNewswire/ -- Dan Skelly joins Platinum Real Estate in Marco Island, Florida.
  • After 10 years as a broker in Colorado Dan wanted to branch out to the fast-paced Florida real estate market.
  • Dan will be working from the Platinum Real Estate office in Marco Island but will work with buyers, sellers, and investors all over Southwest Florida and Colorado.

Pionyr Immunotherapeutics Presents on Third Myeloid-Directed Therapeutic Program at Keystone Symposium

Retrieved on: 
Tuesday, March 22, 2022
Therapy, Sofinnova, Immunosuppression, IND, Tumor microenvironment, Program, Neoplasm, MARCO, Immunity, Poster, SVP, Gilead Sciences, Tams, Tumor-associated macrophage, TREM2, Gilead, New Enterprise Associates, NK, SAN, TREM1, Monocyte, Vaccine, Pharmaceutical industry, Pionýr

SOUTH SAN FRANCISCO, Calif., March 22, 2022 /PRNewswire/ -- Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body's antitumor immunity by altering, or "tuning", immune cells within the tumor microenvironment, announced today preclinical results from its PY265 program demonstrating efficacy both as single-agent and in combination with anti-PD1. The latest preclinical research from the program was presented in a poster at the Keystone Symposium titled Cancer Immunotherapy: Decoding the Cancer Immunity Interactome and in a talk today, March 22.

Key Points: 
  • The latest preclinical research from the program was presented in a poster at the Keystone Symposium titled Cancer Immunotherapy: Decoding the Cancer Immunity Interactome and in a talk today, March 22.
  • MARCO is expressed on immunosuppressive tumor associated macrophages (TAMs) and monocytic myeloid-derived suppressor cells (mMDSCs), and its expression correlates with aggressive and advanced disease.
  • These subpopulations of tumor myeloid cells are different from those that express the targets of Pionyr's current lead clinical programs, TREM1 and TREM2.
  • Pionyr is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics after checkpoint inhibitors.